Combination of vasopressin and angiotensin inhibition in experimental focal glomerulosclerosis

Nephrology

Volumn 3, Issue 5, 1997, Pages 357-367

  Kurihara, Isao ^a   Saito, Takao ^a   Obara, Katsuya ^a   Hirai, Mariko ^a   Soma, Jun ^a   Sato, Hiroshi ^a   Abe, Keishi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Focal glomerulosclerosis; Spontaneously hypercholesterolaemic rat; Vasopressin V1 antagonist

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MIXTURE; DRUG SCREENING; GLOMERULOSCLEROSIS; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030754793     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00255.x     Document Type: Article

References (48)

1. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J. Kidney Dis. 1994; 23: 773-83.
2. Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: Pathology, histological variants, and pathogenesis. Am. J. Kidney Dis. 1993; 22: 874-83.
3. Pei Y, Cattran D, Delmore T, Katz A, Lang A, Rance P. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Am. J. Med. 1987; 82: 938-44.
4. Saito T, Ootaka T, Sato H et al. Participation of macrophages in segmental endocapillary proliferation preceding focal glomerular sclerosis. J. Pathol. 1993; 170: 179-85.
5. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 1982; 307: 652-9.
6. Vassalli P, McCluskey RT. The pathogenic role of the coagulation process in rabbit Masugi nephritis. Am. J. Pathol. 1964; 45: 653-77.
7. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: Analogies to atherosclerosis. Kidney Int. 1988; 33: 917-24.
8. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int. 1989; 35: 654-60.
9. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J. Clin. Invest. 1990; 85: 541-9.
10. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 1990; 38: 384-94.
11. Wolf G. Vasoactive substances as regulators of renal growth. Exp. Nephrol. 1993; 1: 141-51.
12. Carmines PK, Fleming JT. Control of the renal microvasculature by vasoactive peptides. FASEB J. 1990; 4: 3300-9.
13. Wolf G, Neilson EG. Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia. Kidney Int. 1991; 39: 401-20.
14. Daniels BS, Hostetter TH. Adverse effects of growth in the glomerular microcirculation. Am. J. Physiol. 1990; 258: F1409-16.
15. Yamamura Y, Ogawa H, Chihara T et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991; 252: 572-4.
16. Jard S, Lombard C, Marie J, Devilliers G. Vasopressin receptors from cultured mesangial cells resemble V1a type. Am. J. Physiol. 1987; 253: F41-9.
17. Ausiello DA, Kreisberg JI, Roy C, Karnovsky M. Contraction of cultured rat glomerular cells of apparent mesangial origin after stimulation with angiotensin II and arginine vasopressin. J. Clin. Invest. 1980; 65: 754-60.
18. Ganz MB, Pekar SK, Perfetto MC, Sterzel RB. Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am. J. Physiol. 1988; 255: F898-906.
19. Bonventre JV, Skorecki KL, Kreisberg JI, Cheung JY. Vasopressin increases cytosolic free calcium concentration in glomerular mesangial cells. Am. J. Physiol. 1986; 251: F94-102.
20. Imaizumi T, Harada S, Hirooka Y, Masaki H, Momohara M, Takesita A. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. Hypertension 1992; 20: 54-8.
21. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rats. J. Clin. Invest. 1986; 77: 1993-2000.
22. Marinides GN, Groggel GC, Cohen AH, Border WA. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int. 1990; 37: 749-57.
23. Sakemi T, Baba N, Yoshikawa Y. Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 1992; 62: 315-21.
24. Imai Y, Matsumura H, Miyajima H, Oka K. Serum and tissue lipids and glomerulonephritis in the spontaneously hypercholesterolemic rat, with a note on the effect of gonadectomy. Atherosclerosis 1977; 27: 165-78.
25. Yoshikawa Y, Yamasaki K. Renal lesions of hyperlipidemic Imai rats: A spontaneous animal model of focal glomerulosclerosis. Nephron 1991; 59: 471-6.
26. Kondo S, Yoshizawa N, Wakabayashi K. Natural history of renal lesions in spontaneously hypercholesterolemic (SHC) male rats. Jpn. J. Nephrol. 1995; 37: 91-9.
27. Kubo M, Kato J, Ochiai T, Ishida R. Pharmacological studies on (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl) amino] propionyl}-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and anti-hypertensive activities. Jpn. J. Pharmacol. 1990; 53: 201-10.
28. Lowry OH, Rosenbrough NF, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
29. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int. 1987; 32: 691-9.
30. Saito T, Sato H, Obara K, Yamakage K, Abe K, Yoshinaga K. Progression of experimental focal glomerulosclerosis in the spontaneously hypertensive rat. J. Lab. Clin. Med. 1990; 115: 165-73.
31. Kurihara I, Saito T, Obara K, et al. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 1996; 73: 629-36.
32. Bennett WN, Walker RG, Kincaid-Smith P. Renal cortical interstitial volume in mesangial IgA nephropathy: Dissociation from creatinine clearance in serially biopsied patients. Lab. Invest. 1982; 47: 330-5.
33. Van Damme B, Koudstaal J. Measuring glomerular diameters in tissue sections. Virchows Arch. [A] 1976; 369: 283-91.
34. Brooks DP, Solleveld HA, Contino LC. Vasopressin and the pathogenesis of chronic renal failure. Br. J. Pharmacol. 1990; 100: 79-82.
35. Dworkin LD, Grosser M, Feiner HD, Ullian M, Parker M. Renal vascular effects of antihypertensive therapy in uninephrectomized SHR. Kidney Int. 1989; 35: 790-8.
36. Schor N, Ichikawa I, Brenner BM. Mechanisms of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat. Kidney Int. 1981; 20: 442-51.
37. Wolthuis A, Boes A, Rodemann HP, Grond J. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int. 1992; 41: 124-31.
38. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363-6.
39. Kuncio GS, Neilson EG, Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney Int. 1991; 39: 550-6.
40. Kees-Folts D, Sadow JL, Schreiner GF. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int. 1994; 45: 1697-709.
41. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1985; 76: 612-19.
42. Raij L, Keane WF. Glomerular mesangium: Its function and relationship to angiotensin II. Am. J. Med. 1985; 79: 24-30.
43. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988; 33: 667-72.
44. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ. Res. 1988; 62: 367-74.
45. Davies RW, Straprans I, Hutchinson FN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J. Clin. Invest. 1990; 86: 600-5.
46. Assimacopoulos-Jeannet FA, Denton RM, Jeanrenaud B. Stimulation of hepatic lipogenesis and acetyl-coenzyme A carboxylase by vasopressin. Biochem. J. 1981; 198: 485-90.
47. Rossi R, Scharrer E. Mechanisms of the effects of vasopressin on plasma levels of free fatty acids and triglyceride in pygmy goats. Comp. Biochem. Physiol. A. 1993; 104: 287-90.
48. Munter K, Hergenroder S, Jochims K, Kirchengast M. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. J. Am. Soc. Nephrol. 1996; 7: 681-6.